Aswani Thurlapati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aswani Thurlapati has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Alyssa Cendagorta
Department of Pharmacy, Hollings Cancer Center Medical University of South Carolina Charleston South Carolina USA
2 shared publicationsDeidra Smith
Department of Pharmacy, Hollings Cancer Center Medical University of South Carolina Charleston South Carolina USA
2 shared publications- James A. Davis
Medical University of South Carolina, Charleston, SC
2 shared publications Kiera Roubal
Department of Pharmacy, Hollings Cancer Center Medical University of South Carolina Charleston South Carolina USA
2 shared publicationsMary McGann
Department of Pharmacy, Hollings Cancer Center Medical University of South Carolina Charleston South Carolina USA
2 shared publicationsAmanda Herbst
Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center Medical University of South Carolina Charleston South Carolina USA
1 shared publication
Latest Publications
- 7 August 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (8) , e29027
Role of tixagevimab‐cilgavimab in preventing SARS‐CoV‐2 in hematopoietic stem cell transplant and chimeric antigen receptor T‐cell therapy recipients
- 7 August 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (8) , e29027
Role of tixagevimab‐cilgavimab in preventing SARS‐CoV‐2 in hematopoietic stem cell transplant and chimeric antigen receptor T‐cell therapy recipients
- Open Access
- 20 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 340.e1-340.e4
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience
- 20 February 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 340.e1-340.e4
Open AccessStem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience
- Open Access
- 12 April 2022
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 35 (4) , 557-559
Successfully treated acute adult T-cell leukemia with haploidentical stem cell transplantation
Adult T-cell leukemia-lymphoma caused by human T-lymphotropic virus type 1 is a rare and aggressive tumor with high morbidity and mortality. Historically it has been treated with chemotherapy, but more recent studies suggest improvement in survival with the combination of chemotherapy and stem cell transplantation. Our case study reports a middle-aged African American woman with no other risk factors diagnosed with the acute form of adult T-cell leukemia-lymphoma and in remission after completing chemotherapy and a haploidentical stem cell transplantation.
- 12 April 2022
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 35 (4) , 557-559
Open AccessSuccessfully treated acute adult T-cell leukemia with haploidentical stem cell transplantation
Adult T-cell leukemia-lymphoma caused by human T-lymphotropic virus type 1 is a rare and aggressive tumor with high morbidity and mortality. Historically it has been treated with chemotherapy, but more recent studies suggest improvement in survival with the combination of chemotherapy and stem cell transplantation. Our case study reports a middle-aged African American woman with no other risk factors diagnosed with the acute form of adult T-cell leukemia-lymphoma and in remission after completing chemotherapy and a haploidentical stem cell transplantation.
- Open Access
- 22 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15835
Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
The current treatment of choice for polyarthralgia in Crohn’s disease consists of disease-modifying agents and anti-inflammatory therapy, such as anti-tumor-necrosis-factor alpha inhibitors like infliximab. However, here we report the case of a patient with longstanding Crohn’s disease, who developed polyarthritis after receiving only one dose of infliximab. A 57-year-old male with a past medical history of Crohn's disease and stage 1 colon cancer was admitted to our hospital with complaints of polyarticular polyarthralgia, stiffness, and restriction of movements at the joints that started one day prior to admission. It initially began in bilateral wrists, impairing him to hold objects, then spread to bilateral ankles, causing him to fall, and finally affected his jaw, leading to inability to chew or articulate. He received the first dose of infliximab infusion 10 days prior to admission. Labs revealed elevated anti-infliximab antibody levels with low infliximab drug levels. He was treated with steroids, azathioprine, and non-steroidal anti-inflammatory drugs with discontinuation of infliximab. On follow-up, he was initiated on vedolizumab for maintenance of Crohn’s disease and did not develop similar complaints again. Our patient had neither had pre-medication antibodies and positive anti-nuclear antibody, nor received the medication for a long duration as proposed in various studies. He developed severe symptoms affecting the majority of axial skeleton from face to feet just after receiving one dose of infliximab. This suggests that further studies in regard to pathophysiological mechanisms and the dose and duration in correlation to symptoms need to be performed for a better understanding of this disease entity.
- 22 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15835
Open AccessParadoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
The current treatment of choice for polyarthralgia in Crohn’s disease consists of disease-modifying agents and anti-inflammatory therapy, such as anti-tumor-necrosis-factor alpha inhibitors like infliximab. However, here we report the case of a patient with longstanding Crohn’s disease, who developed polyarthritis after receiving only one dose of infliximab. A 57-year-old male with a past medical history of Crohn's disease and stage 1 colon cancer was admitted to our hospital with complaints of polyarticular polyarthralgia, stiffness, and restriction of movements at the joints that started one day prior to admission. It initially began in bilateral wrists, impairing him to hold objects, then spread to bilateral ankles, causing him to fall, and finally affected his jaw, leading to inability to chew or articulate. He received the first dose of infliximab infusion 10 days prior to admission. Labs revealed elevated anti-infliximab antibody levels with low infliximab drug levels. He was treated with steroids, azathioprine, and non-steroidal anti-inflammatory drugs with discontinuation of infliximab. On follow-up, he was initiated on vedolizumab for maintenance of Crohn’s disease and did not develop similar complaints again. Our patient had neither had pre-medication antibodies and positive anti-nuclear antibody, nor received the medication for a long duration as proposed in various studies. He developed severe symptoms affecting the majority of axial skeleton from face to feet just after receiving one dose of infliximab. This suggests that further studies in regard to pathophysiological mechanisms and the dose and duration in correlation to symptoms need to be performed for a better understanding of this disease entity.